232 related articles for article (PubMed ID: 8402714)
1. Recombinant immunotoxins: new therapeutic agents for cancer treatment.
Pastan IH
Cancer Detect Prev; 1993; 17(2):289-93. PubMed ID: 8402714
[TBL] [Abstract][Full Text] [Related]
2. Immunotoxin therapy for cancer.
Pai LH; Pastan I
JAMA; 1993 Jan; 269(1):78-81. PubMed ID: 8416411
[No Abstract] [Full Text] [Related]
3. Recombinant toxins: new therapeutic agents for cancer.
Pastan IH; Pai LH; Brinkmann U; Fitzgerald DJ
Ann N Y Acad Sci; 1995 Jun; 758():345-54. PubMed ID: 7625703
[No Abstract] [Full Text] [Related]
4. Pseudomonas exotoxin: recombinant conjugates as therapeutic agents.
FitzGerald DJ; Pastan I
Biochem Soc Trans; 1992 Nov; 20(4):731-4. PubMed ID: 1487051
[No Abstract] [Full Text] [Related]
5. Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin.
Brinkmann U; Lee BK; Pastan I
J Immunol; 1993 Apr; 150(7):2774-82. PubMed ID: 8454854
[TBL] [Abstract][Full Text] [Related]
6. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.
Brinkmann U; Pai LH; FitzGerald DJ; Willingham M; Pastan I
Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8616-20. PubMed ID: 1924323
[TBL] [Abstract][Full Text] [Related]
7. Recombinant immunotoxins.
Pastan I; Pai LH; Brinkmann U; FitzGerald D
Breast Cancer Res Treat; 1996; 38(1):3-9. PubMed ID: 8825117
[TBL] [Abstract][Full Text] [Related]
8. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.
Reiter Y; Brinkmann U; Jung SH; Lee B; Kasprzyk PG; King CR; Pastan I
J Biol Chem; 1994 Jul; 269(28):18327-31. PubMed ID: 7913461
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
[TBL] [Abstract][Full Text] [Related]
10. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
Benhar I; Pastan I
Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
[TBL] [Abstract][Full Text] [Related]
11. Biotechnological and gene therapeutic strategies in cancer treatment.
Wels W; Moritz D; Schmidt M; Jeschke M; Hynes NE; Groner B
Gene; 1995 Jun; 159(1):73-80. PubMed ID: 7607575
[TBL] [Abstract][Full Text] [Related]
12. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma.
Kreitman RJ; Puri RK; Pastan I
Cancer Res; 1995 Aug; 55(15):3357-63. PubMed ID: 7614471
[TBL] [Abstract][Full Text] [Related]
13. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice.
Kreitman RJ; Hansen HJ; Jones AL; FitzGerald DJ; Goldenberg DM; Pastan I
Cancer Res; 1993 Feb; 53(4):819-25. PubMed ID: 8428363
[TBL] [Abstract][Full Text] [Related]
14. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.
Reiter Y; Wright AF; Tonge DW; Pastan I
Int J Cancer; 1996 Jul; 67(1):113-23. PubMed ID: 8690511
[TBL] [Abstract][Full Text] [Related]
15. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma.
Kreitman RJ; Bailon P; Chaudhary VK; FitzGerald DJ; Pastan I
Blood; 1994 Jan; 83(2):426-34. PubMed ID: 8286741
[TBL] [Abstract][Full Text] [Related]
16. Immunotoxins and recombinant toxins in the treatment of solid carcinomas.
Theuer CP; Pastan I
Am J Surg; 1993 Sep; 166(3):284-8. PubMed ID: 8368439
[TBL] [Abstract][Full Text] [Related]
17. B3(Fab)-PE38M: a recombinant immunotoxin in which a mutant form of Pseudomonas exotoxin is fused to the Fab fragment of monoclonal antibody B3.
Choe M; Webber KO; Pastan I
Cancer Res; 1994 Jul; 54(13):3460-7. PubMed ID: 8012967
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy of cancer with recombinant immunotoxins.
Pastan I
Biochim Biophys Acta; 1997 Oct; 1333(2):C1-6. PubMed ID: 9395287
[No Abstract] [Full Text] [Related]
19. In vitro and in vivo studies of antitumor effects of the recombinant immunotoxin MSH-PE38KDEL on melanoma.
Hui Q; Ma J; Song J; Liu Z; Ren H; Jiang W; Wang Y; Xu Y; Guo D; Zhang X; Lu S
Neoplasma; 2014; 61(4):392-400. PubMed ID: 25027740
[TBL] [Abstract][Full Text] [Related]
20. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
Puri RK; Hoon DS; Leland P; Snoy P; Rand RW; Pastan I; Kreitman RJ
Cancer Res; 1996 Dec; 56(24):5631-7. PubMed ID: 8971168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]